


Paquinimod-d₅-1

Cat. No.:	HY-100442S1		
Molecular Formula:	C ₂₁ H ₁₇ D ₅ N ₂ O ₃		
Molecular Weight:	355.44		
Target:	SARS-CoV; Isotope-Labeled Compounds		
Pathway:	Anti-infection; Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (281.34 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.8134 mL	14.0671 mL	28.1341 mL	
5 mM	0.5627 mL	2.8134 mL	5.6268 mL	
10 mM	0.2813 mL	1.4067 mL	2.8134 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Paquinimod-d₅-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice^{[1][2][3]}.

REFERENCES

- [1]. Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. *Ann Rheum Dis.* 2015 Dec;74(12):2254-8.
- [2]. Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. *Ann Rheum Dis.* 2015 Dec;74(12):2254-8.
- [3]. Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. *Cell Host Microbe.* 2021 Feb 10;29(2):222-235.e4.
- [4]. Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. *PLoS One.* 2018 May 9;13(5):e0196598.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA